Mucosal Immunity Against SARS-CoV-2 in the Respiratory Tract

Overview

Journal Pathogens

Date 2024 Feb 23

PMID 38392851

Authors

Hae-Eun Noh

Min-Seok Rha

Affiliations

Soon will be listed here.

Abstract

The respiratory tract, the first-line defense, is constantly exposed to inhaled allergens, pollutants, and pathogens such as respiratory viruses. Emerging evidence has demonstrated that the coordination of innate and adaptive immune responses in the respiratory tract plays a crucial role in the protection against invading respiratory pathogens. Therefore, a better understanding of mucosal immunity in the airways is critical for the development of novel therapeutics and next-generation vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses. Since the coronavirus disease 2019 pandemic, our knowledge of mucosal immune responses in the airways has expanded. In this review, we describe the latest knowledge regarding the key components of the mucosal immune system in the respiratory tract. In addition, we summarize the host immune responses in the upper and lower airways following SARS-CoV-2 infection and vaccination, and discuss the impact of allergic airway inflammation on mucosal immune responses against SARS-CoV-2.

Citing Articles

Mucosal Inflammatory Memory in Chronic Rhinosinusitis.

Koo M, Moon S, Rha M Cells. 2024; 13(23).

PMID: 39682698 PMC: 11639807. DOI: 10.3390/cells13231947.

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies.

Muthukutty P, MacDonald J, Yoo S Vaccines (Basel). 2024; 12(11).

PMID: 39591123 PMC: 11598775. DOI: 10.3390/vaccines12111220.

References

Oja A, Piet B, Helbig C, Stark R, van der Zwan D, Blaauwgeers H . Trigger-happy resident memory CD4 T cells inhabit the human lungs. Mucosal Immunol. 2017; 11(3):654-667. DOI: 10.1038/mi.2017.94. View

Pieren D, Kuguel S, Rosado J, Robles A, Rey-Cano J, Mancebo C . Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection. Nat Commun. 2023; 14(1):1887. PMC: 10074357. DOI: 10.1038/s41467-023-37559-w. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E . Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry. Viruses. 2021; 13(7). PMC: 8310277. DOI: 10.3390/v13071246. View

Wu T, Hu Y, Lee Y, Bouchard K, Benechet A, Khanna K . Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J Leukoc Biol. 2013; 95(2):215-24. PMC: 3896663. DOI: 10.1189/jlb.0313180. View

Schoggins J, Wilson S, Panis M, Murphy M, Jones C, Bieniasz P . A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. PMC: 3409588. DOI: 10.1038/nature09907. View

Puelles V, Lutgehetmann M, Lindenmeyer M, Sperhake J, Wong M, Allweiss L . Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020; 383(6):590-592. PMC: 7240771. DOI: 10.1056/NEJMc2011400. View

Sui C, Xiao T, Zhang S, Zeng H, Zheng Y, Liu B . SARS-CoV-2 NSP13 Inhibits Type I IFN Production by Degradation of TBK1 via p62-Dependent Selective Autophagy. J Immunol. 2022; 208(3):753-761. DOI: 10.4049/jimmunol.2100684. View

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

10.

Carlier F, De Fays C, Pilette C . Epithelial Barrier Dysfunction in Chronic Respiratory Diseases. Front Physiol. 2021; 12:691227. PMC: 8264588. DOI: 10.3389/fphys.2021.691227. View

11.

Gilbert C, Lefeuvre C, Preisser L, Pivert A, Soleti R, Blanchard S . Age-Related Expression of IFN-λ1 IFN-I and Beta-Defensins in the Nasopharynx of SARS-CoV-2-Infected Individuals. Front Immunol. 2021; 12:750279. PMC: 8631500. DOI: 10.3389/fimmu.2021.750279. View

12.

Scala E, Abeni D, Tedeschi A, Manzotti G, Yang B, Borrelli P . Atopic status protects from severe complications of COVID-19. Allergy. 2020; 76(3):899-902. PMC: 7461535. DOI: 10.1111/all.14551. View

13.

Yamada T, Sato S, Sotoyama Y, Orba Y, Sawa H, Yamauchi H . RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat Immunol. 2021; 22(7):820-828. DOI: 10.1038/s41590-021-00942-0. View

14.

Chen H, Liu P, Liu Y, Kuo S, Zhang X, Schooley R . Nasal commensal Staphylococcus epidermidis counteracts influenza virus. Sci Rep. 2016; 6:27870. PMC: 4910069. DOI: 10.1038/srep27870. View

15.

Ahn J, Kim J, Hong S, Choi S, Yang M, Ju Y . Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. J Clin Invest. 2021; 131(13). PMC: 8245175. DOI: 10.1172/JCI148517. View

16.

Tsukita S, Furuse M, Itoh M . Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001; 2(4):285-93. DOI: 10.1038/35067088. View

17.

Teijaro J, Turner D, Pham Q, Wherry E, Lefrancois L, Farber D . Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol. 2011; 187(11):5510-4. PMC: 3221837. DOI: 10.4049/jimmunol.1102243. View

18.

Kim K, Jung J, Kang I, Choi Y, Kim S . ROS Is Involved in Disruption of Tight Junctions of Human Nasal Epithelial Cells Induced by HRV16. Laryngoscope. 2018; 128(12):E393-E401. DOI: 10.1002/lary.27510. View

19.

Ssemaganda A, Nguyen H, Nuhu F, Jahan N, Card C, Kiazyk S . Expansion of cytotoxic tissue-resident CD8 T cells and CCR6CD161 CD4 T cells in the nasal mucosa following mRNA COVID-19 vaccination. Nat Commun. 2022; 13(1):3357. PMC: 9186487. DOI: 10.1038/s41467-022-30913-4. View

20.

Ray S, Franki S, Pierce R, Dimitrova S, Koteliansky V, Sprague A . The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity. 2004; 20(2):167-79. DOI: 10.1016/s1074-7613(04)00021-4. View